N. C. Allan

TL;DR: A new prognostic scoring system for estimating survival of patients with CML treated with interferon alfa has been developed and validated through use of a large dataset and the ability of the new scoring system to discriminate risk groups was confirmed.

TL;DR: For patients with Philadelphia chromosome-positive chronic myeloid leukemia, the inclusion of IFN alpha in the therapeutic regimen produced substantially better 5-year survival than standard chemotherapy alone.

TL;DR: Presenting features at diagnosis showed no significant difference for those with 5’and 3’breakpoints and those with either b2a2 or b3a2 BCR/ABL transcripts, but in a subgroup of patients whose presenting white‐cell count was <100×p109/1, those with b3 a2 transcript did have a significantly higher platelet count.

TL;DR: The findings show that CML has not been eradicated in any patient and that the quantity of residual disease in complete responders may vary by as much as four orders of magnitude.

TL;DR: Results strongly suggest that the addition of thioguanine was responsible for the development of portal hypertension in 18/675 patients with chronic myeloid leukaemia in a randomized trial comparing busulphan withBusulphan and thiOGuanine.